Login to Your Account

Abbvie sows more post-Humira seeds with some new late-stage RA data

By Michael Fitzhugh
Staff Writer

Wednesday, June 7, 2017

Abbvie Inc.'s late-stage oral JAK1 inhibitor, a candidate that could help fill a key gap in the drugmakers' revenue as Humira's (adalimumab) U.S. market exclusivity lapses, met all primary and secondary endpoints in a phase III RA study.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription